BACKGROUND: Like other premalignant conditions that develop in the presence of chronic inflammation, the development and progression of Barrett's esophagus is associated with the development of an immune response, but how this immune response is regulated is poorly understood. A comprehensive literature search failed to find any report of the presence of dendritic cells in Barrett's intestinal metaplasia and esophageal adenocarcinoma and this prompted our study. MATERIAL AND METHODS: We used immunohistochemical staining and electron microscopy to examine whether dendritic cells are present in Barrett's esophagus and esophageal adenocarcinoma. Immunohistochemical staining with CD83, a specific marker for dendritic cells, was performed on paraffin-embedded sections of Barrett's intestinal metaplasia (IM, n = 12), dysplasia (n = 11) and adenocarcinoma (n = 14). RESULTS: CD83+ cells were identified in the lamina propria surrounding intestinal type glands in Barrett's IM, dysplasia, and cancer tissues. Computerized quantitative analysis showed that the numbers of dendritic cells were significantly higher in cancer tissues. Double immunostaining with CD83, CD20, and CD3, and electron microscopy demonstrated that dendritic cells are present in Barrett's esophagus and form clusters with T cells and B cells directly within the lamina propria. CONCLUSIONS: These findings demonstrate that dendritic cells are present in Barrett's tissues, with a significant increase in density in adenocarcinoma compared to benign Barrett's esophagus. Dendritic cells may have a role in the pathogenesis and immunotherapy treatment of Barrett's esophagus and adenocarcinoma.
BACKGROUND: Like other premalignant conditions that develop in the presence of chronic inflammation, the development and progression of Barrett's esophagus is associated with the development of an immune response, but how this immune response is regulated is poorly understood. A comprehensive literature search failed to find any report of the presence of dendritic cells in Barrett's intestinal metaplasia and esophageal adenocarcinoma and this prompted our study. MATERIAL AND METHODS: We used immunohistochemical staining and electron microscopy to examine whether dendritic cells are present in Barrett's esophagus and esophageal adenocarcinoma. Immunohistochemical staining with CD83, a specific marker for dendritic cells, was performed on paraffin-embedded sections of Barrett's intestinal metaplasia (IM, n = 12), dysplasia (n = 11) and adenocarcinoma (n = 14). RESULTS:CD83+ cells were identified in the lamina propria surrounding intestinal type glands in Barrett's IM, dysplasia, and cancer tissues. Computerized quantitative analysis showed that the numbers of dendritic cells were significantly higher in cancer tissues. Double immunostaining with CD83, CD20, and CD3, and electron microscopy demonstrated that dendritic cells are present in Barrett's esophagus and form clusters with T cells and B cells directly within the lamina propria. CONCLUSIONS: These findings demonstrate that dendritic cells are present in Barrett's tissues, with a significant increase in density in adenocarcinoma compared to benign Barrett's esophagus. Dendritic cells may have a role in the pathogenesis and immunotherapy treatment of Barrett's esophagus and adenocarcinoma.
Authors: William R Heath; Gabrielle T Belz; Georg M N Behrens; Christopher M Smith; Simon P Forehan; Ian A Parish; Gayle M Davey; Nicholas S Wilson; Francis R Carbone; Jose A Villadangos Journal: Immunol Rev Date: 2004-06 Impact factor: 12.988
Authors: A R Dadabayev; M H Sandel; A G Menon; H Morreau; C J M Melief; R Offringa; S H van der Burg; C Janssen-van Rhijn; N G Ensink; R A E M Tollenaar; C J H van de Velde; P J K Kuppen Journal: Cancer Immunol Immunother Date: 2004-06-17 Impact factor: 6.968
Authors: Francesca Milano; Agnieszka M Rygiel; Navtej Buttar; Jacques J G H M Bergman; Carine Sondermeijer; Jantine W P M van Baal; Anja ten Brinke; Martien Kapsenberg; S Marieke van Ham; Maikel P Peppelenbosch; Kausilia K Krishnadath Journal: Cancer Immunol Immunother Date: 2007-06-13 Impact factor: 6.968
Authors: Natalie To; Richard P T Evans; Hayden Pearce; Sivesh K Kamarajah; Paul Moss; Ewen A Griffiths Journal: Cancers (Basel) Date: 2022-06-24 Impact factor: 6.575
Authors: Yuri V Bobryshev; Dinh Tran; Murray C Killingsworth; Michael Buckland; Reginald V N Lord Journal: J Gastrointest Surg Date: 2008-11-18 Impact factor: 3.452
Authors: Alexandra Lind; Peter D Siersema; Johannes G Kusters; Jan A M Van der Linden; Edward F Knol; Leo Koenderman Journal: PLoS One Date: 2012-04-03 Impact factor: 3.240
Authors: Cathryn M Kolka; Julie Webster; Ailin Lepletier; Clay Winterford; Ian Brown; Renee S Richards; Wioleta M Zelek; Yilang Cao; Ramlah Khamis; Karthik B Shanmugasundaram; Alain Wuethrich; Matt Trau; Sandra Brosda; Andrew Barbour; Alok K Shah; Guy D Eslick; Nicholas J Clemons; B Paul Morgan; Michelle M Hill Journal: Front Immunol Date: 2022-03-08 Impact factor: 8.786
Authors: Jeffrey W Prichard; Jon M Davison; Bruce B Campbell; Kathleen A Repa; Lia M Reese; Xuan M Nguyen; Jinhong Li; Tyler Foxwell; D Lansing Taylor; Rebecca J Critchley-Thorne Journal: J Pathol Inform Date: 2015-08-31